Company Profile
Viracta Therapeutics Stock Price, News & Analysis
- Ticker:
- VIRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for VIRX.
Company overview
Business overview
Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology. Its platform aims to treat tumors linked to latent viral drivers.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Viracta sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, target differentiation, and the ability to build a focused oncology franchise.
Position Within the Biotechnology Landscape
Viracta is a catalyst-sensitive oncology name whose stock reacts to early clinical and strategic updates.
Future catalysts
Viracta’s catalysts are nanatinostat-based programs in EBV-positive lymphomas and any development update that keeps the antiviral-oncology story alive. The company still needs strong human data.
Recent news
- 01
Viracta Therapeutics Announces Wind Down of Operations
Source: Viracta Therapeutics
- 02
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Source: Viracta Therapeutics
- 03
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Source: Viracta Therapeutics
- 04
- 05
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Source: Viracta Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Viracta Therapeutics do?
Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology. Its platform aims to treat tumors linked to latent viral drivers.
On which exchange is VIRX stock listed?
Viracta Therapeutics (VIRX) is associated with NASDAQ, United States, Biopharma.
What is nanatinostat?
Viracta’s catalysts are nanatinostat-based programs in EBV-positive lymphomas and any development update that keeps the antiviral-oncology story alive.
Which conditions is Viracta Therapeutics targeting with nanatinostat?
Viracta Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Viracta Therapeutics describe recent progress with nanatinostat?
Viracta’s catalysts are nanatinostat-based programs in EBV-positive lymphomas and any development update that keeps the antiviral-oncology story alive.
What is Viracta?
Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology.
What should investors watch for with Viracta?
Viracta’s catalysts are nanatinostat-based programs in EBV-positive lymphomas and any development update that keeps the antiviral-oncology story alive.
What is Therapeutics?
Viracta Therapeutics is an oncology company focused on virus-associated cancers and targeted cancer biology.